Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada

Authors :: Zhu, Katie Y.
Song, Kevin W.
Connors, Joseph M
Tucker, Tracy
Slack, Graham W.
Abou Mourad, Yasser
Barnett, Michael J
Forrest, Donna L.
Hogge, Donna E.
Nantel, Stephen H.
Narayanan, Sujaatha
Nevill, Thomas J.
Power, Maryse M
Sanford, David
Toze, Cynthia L.
Sutherland, Heather J.
Sehn, Laurie H.
Broady, Raewyn
Gerrie, Alina S.
Source :: Blood; December 2016, Vol. 128 Issue: 22 p1113-1113, 1p
Publication Year :: 2016
Abstract: Song: Celgene: Honoraria, Research Funding; Otsuka: Honoraria; Janssen: Honoraria. Connors:Roche Canada: Research Funding. Toze:Roche Canada: Research Funding. Broady:Lotte & John Hecht Memorial Foundation: Research Funding. Gerrie:Roche Canada: Research Funding.

Full Text Access

Tools